Partial depletion of striatal dopamine enhances penetrance of cognitive deficits in a transgenic mouse model of Alzheimer's disease

Journal of Neuroscience Research

Volumn 93, Issue 9, 2015, Pages 1413-1422

  Melief, Erica J ^a   Cudaback, Eiron ^a   Jorstad, Nikolas L ^a   Sherfield, Emily ^a   Postupna, Nadia ^a   Wilson, Angela ^a   Darvas, Martin ^a   Montine, Kathleen S ^a   Keene, C Dirk ^a   Montine, Thomas J ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

6OHDA; Alzheimer's disease; Amyloid; Cognitive impairment; Parkinson's disease

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; DOPAMINE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; ADRENERGIC RECEPTOR STIMULATING AGENT; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; OXIDOPAMINE; PRESENILIN 1; PSEN1 PROTEIN, HUMAN;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BARNES MAZE TEST; COGNITIVE DEFECT; CONTROLLED STUDY; CORPUS STRIATUM; DENDRITE; DISEASE EXACERBATION; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; INNERVATION; MORRIS WATER MAZE TEST; MOUSE; NERVE CELL CULTURE; NERVE DEGENERATION; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENILE PLAQUE; TASK PERFORMANCE; TRANSGENIC MOUSE; ANALYSIS OF VARIANCE; ANIMAL; CHEMICALLY INDUCED; COMPLICATION; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; GENETICS; HUMAN; MAZE TEST; METABOLISM; MOTOR ACTIVITY; MUTATION; PATHOLOGY; PENETRANCE; PHYSIOLOGY;

ADRENERGIC AGENTS; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANALYSIS OF VARIANCE; ANIMALS; COGNITION DISORDERS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; HUMANS; MAZE LEARNING; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; MUTATION; OXIDOPAMINE; PENETRANCE; PRESENILIN-1;

EID: 84947916119     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.23592     Document Type: Article

References (32)

1. Aarsland D, Kurz MW. 2010. The epidemiology of dementia associated with Parkinson's disease. Brain Pathol 20:633-639.
2. Alves G, Brønnick K, Aarsland D, Blennow K, Zetterberg H, Ballard C, Kurz MW, Andreasson U, Tysnes O-B, Larsen JP, Mulugeta E. 2010. CSF amyloid-β and tau proteins and cognitive performance in early and untreated Parkinson's disease: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry 81:1080-1086.
3. Alves G, Lange J, Blennow K, Zetterberg H, Andreasson U, Førland MG, Tysnes O-B, Larsen JP, Pedersen KF. 2014. CSF Aβ42 predicts early-onset dementia in Parkinson disease. Neurology 82:1784-1790.
4. Barr AM, MacLaurin SA, Semenova S, Fish KN, Markou A. 2007. Altered performance of reelin-receptor ApoER2 deficient mice on spatial tasks using the Barnes maze. Behav Neurosci 121:1101-1105.
5. CDC-Healthy Brain Initiative. n.d. Healthy brain initiative: road map-aging. http://www.cdc.gov/aging/healthybrain/roadmap.htm (accessed 11/20/14).
6. Cimino PJ, Yang Y, Li X, Hemingway JF, Cherne MK, Khademi SB, Fukui Y, Montine KS, Montine TJ, Keene CD. 2013. Ablation of the microglial protein DOCK2 reduces amyloid burden in a mouse model of Alzheimer's disease. Exp Mol Pathol 94:366-371.
7. Clinton LK, Blurton-Jones M, Myczek K, Trojanowski JQ, LaFerla FM. 2010. Synergistic interactions between Aβ, tau, and α-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci 30:7281-7289.
8. Darvas M, Palmiter RD. 2011. Contributions of striatal dopamine signaling to the modulation of cognitive flexibility. Biol Psychiatry 69:704-707.
9. Dugger BN, Serrano GE, Sue LI, Walker DG, Adler CH, Shill HA, Sabbagh MN, Caviness JN, Hidalgo J, Saxon-LaBelle M, Chiarolanza G, Mariner M, Henry-Watson J, Beach TG. 2012. Presence of striatal amyloid plaques in Parkinson's disease dementia predicts concomitant Alzheimer's disease: usefulness for amyloid imaging. J Parkinsons Dis 2:57-65.
10. Feldman AL, Johansson ALV, Lambert PC, Sieurin J, Yang F, Pedersen NL, Wirdefeldt K. 2014a. Familial coaggregation of Alzheimer's disease and Parkinson's disease: systematic review and meta-analysis. Neuroepidemiology 42:69-80.
11. Feldman AL, Wirdefeldt K, Johansson ALV, Gatz M, Pedersen NL. 2014b. Evidence for modest familial coaggregation between dementia and parkinsonism. Eur J Epidemiol 29:49-56.
12. Garcia-Alloza M, Robbins EM, Zhang-Nunes SX, Purcell SM, Betensky RA, Raju S, Prada C, Greenberg SM, Bacskai BJ, Frosch MP. 2006. Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol Dis 24:516-524.
13. Gomperts SN, Rentz DM, Moran E, Becker JA, Locascio JJ, Klunk WE, Mathis CA, Elmaleh DR, Shoup T, Fischman AJ, Hyman BT, Growdon JH, Johnson KA. 2008. Imaging amyloid deposition in Lewy body diseases. Neurology 71:903-910.
14. Guo JL, Covell DJ, Daniels JP, Iba M, Stieber A, Zhang B, Riddle DM, Kwong LK, Xu Y, Trojanowski JQ, Lee VMY. 2013. Distinct α-synuclein strains differentially promote tau inclusions in neurons. Cell 154.
15. Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Thies B, Trojanowski JQ, Vinters HV, Montine TJ. 2012. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement 8:1-13.
16. Irwin DJ, White MT, Toledo JB, Xie SX, Robinson JL, Van Deerlin V, Lee VM-Y, Leverenz JB, Montine TJ, Duda JE, Hurtig HI, Trojanowski JQ. 2012. Neuropathologic substrates of Parkinson disease dementia. Ann Neurol 72:587-598.
17. Jürgensen S, Antonio LL, Mussi GEA, Brito-Moreira J, Bomfim TR, Felice FGD, Garrido-Sanabria ER, Cavalheiro ÉA, Ferreira ST. 2011. Activation of D1/D5 dopamine receptors protects neurons from synapse dysfunction induced by amyloid-β oligomers. J Biol Chem 286:3270-3276.
18. Klunk WE, Price JC, Mathis CA, Tsopelas ND, Lopresti BJ, Ziolko SK, Bi W, Hoge JA, Cohen AD, Ikonomovic MD, Saxton JA, Snitz BE, Pollen DA, Moonis M, Lippa CF, Swearer JM, Johnson KA, Rentz DM, Fischman AJ, Aizenstein HJ, DeKosky ST. 2007. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci 27:6174-6184.
19. Li X, Rose S, Montine K, Keene CD, Montine TJ. 2013. Antagonism of neuronal prostaglandin E2 receptor subtype 1 mitigates amyloid β neurotoxicity in vitro. J Neuroimmune Pharmacol 8:87-93.
20. Marder K, Tang MX, Cote L, Stern Y, Mayeux R. 1995. The frequency and associated risk factors for dementia in patients with Parkinson's disease. Arch Neurol 52:695-701.
21. Montine TJ, Shi M, Quinn JF, Peskind ER, Craft S, Ginghina C, Chung KA, Kim H, Galasko DR, Jankovic J, Zabetian CP, Leverenz JB, Zhang J. 2010. CSF Aβ42 and tau in Parkinson's disease with cognitive impairment. Mov Disord 25:2682-2685.
22. Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Trojanowski JQ, Vinters HV, Hyman BT. 2012. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol 123:1-11.
23. Montine TJ, Koroshetz WJ, Babcock D, Dickson DW, Galpern WR, Glymour MM, Greenberg SM, Hutton ML, Knopman DS, Kuzmichev AN, Manly JJ, Marder KS, Miller BL, Phelps CH, Seeley WW, Sieber B-A, Silverberg NB, Sutherland M, Torborg CL, Waddy SP, Zlokovic BV, Corriveau RA. 2014. Recommendations of the Alzheimer's disease-related dementias conference. Neurology 83:851-860.
24. Nation DA, Hong S, Jak AJ, Delano-Wood L, Mills PJ, Bondi MW, Dimsdale JE. 2011. Stress, exercise, and Alzheimer's disease: a neurovascular pathway. Med Hypoth 76:847-854.
25. Obeso JA, Rodríguez-Oroz MC, Rodríguez M, Lanciego JL, Artieda J, Gonzalo N, Olanow CW. 2000. Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci 23:S8-S19.
26. Postupna N, Keene CD, Crane PK, Gonzalez-Cuyar LF, Sonnen JA, Hewitt J, Rice S, Howard K, Montine KS, Larson EB, Montine TJ. 2015. Cerebral cortical Aβ42 and PHF-τ in 325 consecutive brain autopsies stratified by diagnosis, location, and APOE. J Neuropathol Exp Neurol 74:100-109.
27. Siderowf A, Xie SX, Hurtig H, Weintraub D, Duda J, Chen-Plotkin A, Shaw LM, Deerlin VV, Trojanowski JQ, Clark C. 2010. CSF amyloid β 1-42 predicts cognitive decline in Parkinson disease. Neurology 75:1055-1061.
28. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH. 2011. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7:280-292.
29. Woltjer RL, Sonnen JA, Sokal I, Rung LG, Yang W, Kjerulf JD, Klingert D, Johnson C, Rhew I, Tsuang D, Crane PK, Larson EB, Montine TJ. 2009. Quantitation and mapping of cerebral detergent-insoluble proteins in the elderly. Brain Pathol 19:365-374.
30. Yang Y, Cudaback E, Jorstad NL, Hemingway JF, Hagan CE, Melief EJ, Li X, Yoo T, Khademi SB, Montine KS, Montine TJ, Keene CD. 2013. APOE3, but not APOE4, bone marrow transplantation mitigates behavioral and pathological changes in a mouse model of Alzheimer disease. Am J Pathol 183:905-917.
31. Zaja-Milatovic S, Milatovic D, Schantz AM, Zhang J, Montine KS, Samii A, Deutch AY, Montine TJ. 2005. Dendritic degeneration in neostriatal medium spiny neurons in Parkinson disease. Neurology 64:545-547.
32. Zaja-Milatovic S, Keene CD, Montine KS, Leverenz JB, Tsuang D, Montine TJ. 2006. Selective dendritic degeneration of medium spiny neurons in dementia with Lewy bodies. Neurology 66:1591-1593.